Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

NCT05327010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions

DRUG: BET Bromodomain Inhibitor ZEN-3694
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Diagnostic Imaging Testing
DRUG: Talazoparib

Sponsor

National Cancer Institute (NCI)